Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To examine whether attention-deficit/hyperactivity disorder (ADHD) stimulant medication modified the linear growth response to growth hormone (GH) treatment in children enrolled in the American Norditropin Studies: Web-Enabled Research Program.

Who Took Part

By PubMed's age tags, the people studied were children, both men and women.

Short, GH treatment-naive children with or without GH deficiency (GHD) received GH therapy.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

A subset also received ADHD stimulant medication (n = 1190), and others did not (n = 7230).

Linear mixed models (adjusted means) examined height SDS (HSDS) and body mass index (BMI) SDS from baseline through year 4.

Analyses were repeated with ADHD groups matched for baseline age, height, weight, BMI, and sex.

Groups with and without GHD were compared between ADHD groups.

What Was Measured

Topics PubMed links to this paper include Attention Deficit Disorder with Hyperactivity, Body Height, Body Mass Index, Central Nervous System Stimulants and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (The Journal of pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.